Previous Close | 42.29 |
Open | 42.51 |
Bid | 43.71 x 1400 |
Ask | 43.87 x 1000 |
Day's Range | 42.51 - 46.31 |
52 Week Range | 9.08 - 63.40 |
Volume | |
Avg. Volume | 709,626 |
Market Cap | 2.618B |
Beta (5Y Monthly) | 1.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.06 |
Earnings Date | Nov 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 69.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for MLTX
MLTX Advances in Clinical Trials with Strong Cash Position
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa Presented positive 12-week data from the global Phase 2 MIRA clinical trial for sonelokimab in hidradenitis suppurativa at a late-breaking session during the European Academy of Dermat
MoonLake Immunotherapeutics reported mixed test results for its psoriatic arthritis treatment on Monday, and top-rated MLTX stock crashed.